News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
HIPEC improves overall survival in recurrent epithelial ovarian cancer
Jean-Marc Classe/vjoncology.com
Nov 20, 2024, 20:27

HIPEC improves overall survival in recurrent epithelial ovarian cancer

Pramesh CS, Director at Tata Memorial Hospital, shared a recent article by Jean-Marc Classe on X:

“HIPEC improves overall survival in recurrent epithelial ovarian cancer. Level 1 evidence now. Took 10 years to do the trial, but these are the kinds of trials we need. Surgical trials, with overall survival (not DFS) as endpoint.”

Title: Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial

Authors: Jean-Marc Classe, Pierre Meeus, Delphine Hudry, Romuald Wernert, François Quenet, Frédéric Marchal,  Gilles Houvenaeghel, Anne-Sophie Bats, Fabrice Lecuru, Gwenaël Ferron, Cécile Brigand, Dominique Berton, Laurence Gladieff, Florence Joly, Isabelle Ray-Coquard, Sylvaine Durand-Fontanier, Gabriel Liberale, Marc Pocard, Constantin Georgeac, Sébastien Gouy, Jean-Marc Guilloit, Frédéric Guyon, Cristina Costan, Jean-Marc Rousselet,  Lara de Guerké, Naoual Bakrin, Emilie Brument, Elodie Martin, Bernard Asselain, Loïc Campion and  Olivier Glehen

HIPEC improves overall survival in recurrent epithelial ovarian cancer
More posts featuring Pramesh CS.
Bernard Asselain cancer chemotherapy Delphine Hudry Elodie Martin epithelial ovarian cancer HIPEC Jean-Marc Classe Loïc Campion Olivier Glehen OncoDaily Oncology Ovarian Cancer Pierre Meeus Pramesh CS Romuald Wernert
Special Coverage
Insight
Nov 20, 2024, 20:27
HIPEC improves overall survival in recurrent epithelial ovarian cancer
Blog
Nov 20, 2024, 19:12
Medicaid Cancer Foundation at 1Ummah Annual Convention
Insight
Nov 20, 2024, 19:12
Sahar Mansour: Advancing Breast Microcalcification Detection with AI
Blog
Nov 20, 2024, 19:12
Reflecting on Progress and Partnerships in Lung Cancer Care – Sarah Cannon Research Institute
Blog
Nov 20, 2024, 19:12
Virtual tumor board on the management of a patient with Metastatic Squamous NSCLC - IASLC
Insight
Nov 20, 2024, 19:12
Nareg Varjabedian: Antidiabetic Drugs and Cancer Prevention
Insight
Nov 20, 2024, 19:12
Paolo Ciracì: Late-line options for patients with metastatic colorectal cancer
Insight
Nov 20, 2024, 19:12
Physicians’ perspectives on cancer-related fatigue management: A cross-sectional survey study in Germany - MASCC
Insight
Nov 20, 2024, 19:12
Ajay Major: Golcadomide and R-CHOP as first line for LBCL by Arnaud Amzallag et al.
Blog
Nov 20, 2024, 19:12
Rahul Gosain: Role of diet and exercise in cancer with Neil Iyengar
Insight
Nov 20, 2024, 19:11
Nina Niu Sanford: First clinical PULSAR study is out
Blog
Nov 20, 2024, 18:33
Bernard A. Fox: R. Bryan Bell has accepted the roles of executive medical director of Providence Cancer Institute